CL2013003728A1 - Antagonist antibody or fragment thereof that binds to human ox40; epitope of the human ox40 extracellular domain that is bound by the aforementioned antibody; nucleic acid encoding the antibody; vector and host cell comprising said nucleic acid; method to produce the antibody; composition comprising the antibody; immunoconjugate; use to treat disorders mediated by ox40. - Google Patents
Antagonist antibody or fragment thereof that binds to human ox40; epitope of the human ox40 extracellular domain that is bound by the aforementioned antibody; nucleic acid encoding the antibody; vector and host cell comprising said nucleic acid; method to produce the antibody; composition comprising the antibody; immunoconjugate; use to treat disorders mediated by ox40.Info
- Publication number
- CL2013003728A1 CL2013003728A1 CL2013003728A CL2013003728A CL2013003728A1 CL 2013003728 A1 CL2013003728 A1 CL 2013003728A1 CL 2013003728 A CL2013003728 A CL 2013003728A CL 2013003728 A CL2013003728 A CL 2013003728A CL 2013003728 A1 CL2013003728 A1 CL 2013003728A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- human
- nucleic acid
- epitope
- fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
LA INVENCIÓN PROPORCIONA A UN ANTICUERPO ANTAGONISTA O FRAGMENTO DEL MISMO QUE SE UNE A OX40 DE HUMANO; EPITOPE DEL DOMINIO EXTRACELULAR DE OX40 DE HUMANO QUE ES UNIDO POR EN ANTICUERPO ANTES MENCIONADO; ACIDO NUCLEICO QUE CODIFICA EL ANTICUERPO; VECTOR Y CÉLULA HOSPEDERA QUE COMPRENDEN DICHO ACIDO NUCLEICO; METODO PARA PRODUCIR EL ANTICUERPO; COMPOSICION QUE COMPRENDE EL ANTICUERPO; INMUNOCONJUGADO; USO PARA TRATAR TRASTORNOS MEDIADOS POR OX40.THE INVENTION PROVIDES AN ANTAGONIST ANTIBODY OR FRAGMENT OF THE SAME THAT JOINS OX40 OF HUMAN; EPITOPE OF THE EXTRACELLULAR DOMAIN OF OX40 OF HUMAN THAT IS UNITED BY IN ANTIBODY BEFORE MENTIONED; NUCLEIC ACID CODING THE ANTIBODY; VECTOR AND HOSPEDERA CELL THAT UNDERSTAND SUCH NUCLEIC ACID; METHOD TO PRODUCE THE ANTIBODY; COMPOSITION THAT THE ANTIBODY UNDERSTANDS; IMMUNOCONJUGADO; USE TO TREAT OX40 DISORDERS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506491P | 2011-07-11 | 2011-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003728A1 true CL2013003728A1 (en) | 2014-10-17 |
Family
ID=46601863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003728A CL2013003728A1 (en) | 2011-07-11 | 2013-12-26 | Antagonist antibody or fragment thereof that binds to human ox40; epitope of the human ox40 extracellular domain that is bound by the aforementioned antibody; nucleic acid encoding the antibody; vector and host cell comprising said nucleic acid; method to produce the antibody; composition comprising the antibody; immunoconjugate; use to treat disorders mediated by ox40. |
Country Status (29)
Country | Link |
---|---|
US (5) | US8748585B2 (en) |
EP (1) | EP2731677B1 (en) |
JP (3) | JP6261499B2 (en) |
KR (2) | KR20200067220A (en) |
CN (2) | CN107915775B (en) |
AP (1) | AP2014007415A0 (en) |
AU (2) | AU2012282116B2 (en) |
BR (1) | BR112014000630A2 (en) |
CA (2) | CA3158257A1 (en) |
CL (1) | CL2013003728A1 (en) |
CO (1) | CO7020848A2 (en) |
CY (1) | CY1120414T1 (en) |
DK (1) | DK2731677T3 (en) |
EA (1) | EA036047B1 (en) |
ES (1) | ES2670621T3 (en) |
HK (1) | HK1253936A1 (en) |
HR (1) | HRP20180858T1 (en) |
HU (1) | HUE037700T2 (en) |
IL (1) | IL259979A (en) |
LT (1) | LT2731677T (en) |
MX (1) | MX353931B (en) |
PE (1) | PE20142243A1 (en) |
PL (1) | PL2731677T3 (en) |
PT (1) | PT2731677T (en) |
SI (1) | SI2731677T1 (en) |
TR (1) | TR201807040T4 (en) |
UA (1) | UA116873C2 (en) |
WO (1) | WO2013008171A1 (en) |
ZA (1) | ZA201400254B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10196450B2 (en) | 2010-08-23 | 2019-02-05 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE042114T2 (en) * | 2009-02-17 | 2019-06-28 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
WO2012023614A1 (en) | 2010-08-20 | 2012-02-23 | 学校法人 城西大学 | Monoclonal antibody having immunosuppressive activity or fragment to which antigen thereof is bonded |
PE20142243A1 (en) * | 2011-07-11 | 2015-01-11 | Glenmark Pharmaceuticals Sa | ANTIBODIES THAT BIND OX40 AND ITS USES |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
CN104968364A (en) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | Enhancing anti-cancer activity of immunomodulatory Fc fusion proteins |
CN105188749B (en) | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | Anti- NTB A antibody and compositions related and method |
MX2015013288A (en) | 2013-03-18 | 2016-04-07 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof. |
JP2016538275A (en) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ, エセ.アー. | Production of T-cell retargeting heterodimeric immunoglobulins |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
HUE048782T2 (en) * | 2014-03-10 | 2020-08-28 | Richter Gedeon Nyrt | Immunoglobulin purification using pre-cleaning steps |
KR20230097209A (en) * | 2014-03-12 | 2023-06-30 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
AU2015241038A1 (en) | 2014-03-31 | 2016-10-13 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists |
EA201692458A1 (en) | 2014-05-28 | 2017-06-30 | Агенус Инк. | ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION |
TW201619200A (en) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | Humanized anti-OX40 antibodies and uses thereof |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
JP6744326B2 (en) | 2015-01-08 | 2020-08-19 | バイオエヌテック エスエーBiontech Se | Agonist TNF receptor binding substance |
PT3265123T (en) | 2015-03-03 | 2023-02-01 | Kymab Ltd | Antibodies, uses & methods |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
TW201709932A (en) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | CD123 antibodies and conjugates thereof |
CN108602887B (en) | 2015-10-02 | 2022-06-21 | 豪夫迈·罗氏有限公司 | Bispecific antibodies specific for co-stimulatory TNF receptors |
WO2017063162A1 (en) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | Anti-ox40 antibody and application thereof |
EP3383430A4 (en) * | 2015-12-02 | 2019-12-18 | Agenus Inc. | Antibodies and methods of use thereof |
WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
DE102016105069A1 (en) | 2016-03-18 | 2017-09-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Antiviral immunotherapy by membrane receptor ligation |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
UA126905C2 (en) * | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Anti-pd-l1 antibodies and uses thereof |
KR102531889B1 (en) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | Anti-PD-L1 and IL-2 cytokines |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3538152A4 (en) * | 2016-11-09 | 2020-09-30 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
US11242398B2 (en) * | 2017-08-01 | 2022-02-08 | Remd Biotherapeutics, Inc. | Anti-OX40 antibodies and methods of activating OX40 |
US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
CN108218990B (en) * | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | Isolated antibodies or antigen binding fragments thereof and their use in tumor therapy |
BR112020023026A2 (en) * | 2018-05-11 | 2021-02-09 | WuXi Biologics Ireland Limited | fully human antibodies against ox40, a method for its preparation and use |
US20210214453A1 (en) * | 2018-05-18 | 2021-07-15 | Ichnos Sciences SA | Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases |
EP3802600A1 (en) * | 2018-05-31 | 2021-04-14 | Ichnos Sciences S.A. | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders |
CN112638375A (en) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | Increasing immune activity through modulation of post-cellular signaling factors |
US20210355229A1 (en) * | 2018-09-26 | 2021-11-18 | Jiangsu Hengrui Medicine Co., Ltd. | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
US20220017632A1 (en) * | 2018-12-25 | 2022-01-20 | Hanx Biopharmaceutics, Inc | Anti-ox40 monoclonal antibody and application thereof |
US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
US11634501B2 (en) | 2019-07-19 | 2023-04-25 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
BR112022011949A2 (en) | 2019-12-17 | 2022-11-22 | Amgen Inc | INTERLEUKIN-2/TNF RECEPTOR AGONIST DUAL FOR USE IN THERAPY |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN113045655A (en) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | anti-OX 40 antibodies and uses thereof |
CA3175407A1 (en) | 2020-04-17 | 2021-10-21 | Yizhen Yang | Anti-ox40 antibody and uses thereof |
US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
JP2024500847A (en) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | Chimeric antigen receptor systems with compatible receptor specificities |
CN114685658A (en) * | 2020-12-30 | 2022-07-01 | 百力司康生物医药(杭州)有限公司 | OX40 targeted antibody and preparation method and application thereof |
AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Duplexbodies |
AU2023219227A1 (en) | 2022-02-09 | 2024-08-01 | Petmedix Ltd | Therapeutic antibodies |
WO2024056862A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | CHANGED ANTIBODIES. |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (en) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
ATE199392T1 (en) | 1992-12-04 | 2001-03-15 | Medical Res Council | MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5924939A (en) | 1996-09-10 | 1999-07-20 | Cobra Golf Incorporated | Golf club head with a strike face having a first insert within a second insert |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
MXPA04003798A (en) | 2001-10-25 | 2004-07-30 | Genentech Inc | Glycoprotein compositions. |
US7365167B2 (en) * | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
US6875433B2 (en) * | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
CN1717418B (en) * | 2002-11-29 | 2011-03-30 | Rsr有限公司 | Antibody for the thyrotropin receptor and uses thereof |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
MX2009003393A (en) * | 2006-10-02 | 2009-05-11 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor. |
CL2008000578A1 (en) * | 2007-02-27 | 2008-10-10 | Genentech Inc | ANTI-BODY INSTRUMENT ISOLATED ANTI-RECEIVER OX40 HUMAN; NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; COMPOSITION THAT UNDERSTANDS IT; ITS USE TO TREAT OX40 DISORDERS; AND METHOD TO DETECT |
SI2851374T1 (en) * | 2007-12-14 | 2017-08-31 | Bristol-Myers Squibb Company | Binding molecules to the human OX40 receptor |
HUE042114T2 (en) | 2009-02-17 | 2019-06-28 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
BRPI1005984A2 (en) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | humanized antibody or fragment thereof that binds to human cd19, isolated nucleic acid, vector, host cell, method for producing a humanized antibody or fragment thereof that binds to human cd12, composition, immunoconjugate, use of humanized antibody or fragment of the same, article of manufacture and kit |
WO2012023614A1 (en) | 2010-08-20 | 2012-02-23 | 学校法人 城西大学 | Monoclonal antibody having immunosuppressive activity or fragment to which antigen thereof is bonded |
AU2011293558B2 (en) * | 2010-08-23 | 2014-07-31 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
WO2012096418A1 (en) * | 2011-01-12 | 2012-07-19 | (주) 콜게이트 | System and method for providing a screen switching service during call counseling and device applied thereto |
PE20142243A1 (en) * | 2011-07-11 | 2015-01-11 | Glenmark Pharmaceuticals Sa | ANTIBODIES THAT BIND OX40 AND ITS USES |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2012
- 2012-07-09 PE PE2014000037A patent/PE20142243A1/en active IP Right Grant
- 2012-07-09 ES ES12741386.2T patent/ES2670621T3/en active Active
- 2012-07-09 CA CA3158257A patent/CA3158257A1/en active Pending
- 2012-07-09 WO PCT/IB2012/053502 patent/WO2013008171A1/en active Application Filing
- 2012-07-09 PT PT127413862T patent/PT2731677T/en unknown
- 2012-07-09 TR TR2018/07040T patent/TR201807040T4/en unknown
- 2012-07-09 EP EP12741386.2A patent/EP2731677B1/en active Active
- 2012-07-09 JP JP2014519668A patent/JP6261499B2/en active Active
- 2012-07-09 LT LTEP12741386.2T patent/LT2731677T/en unknown
- 2012-07-09 SI SI201231307T patent/SI2731677T1/en unknown
- 2012-07-09 AP AP2014007415A patent/AP2014007415A0/en unknown
- 2012-07-09 PL PL12741386T patent/PL2731677T3/en unknown
- 2012-07-09 KR KR1020207015702A patent/KR20200067220A/en active Search and Examination
- 2012-07-09 DK DK12741386.2T patent/DK2731677T3/en active
- 2012-07-09 CA CA2840460A patent/CA2840460C/en active Active
- 2012-07-09 KR KR1020147003602A patent/KR102119840B1/en active IP Right Grant
- 2012-07-09 BR BR112014000630A patent/BR112014000630A2/en not_active Application Discontinuation
- 2012-07-09 CN CN201711281808.1A patent/CN107915775B/en active Active
- 2012-07-09 HU HUE12741386A patent/HUE037700T2/en unknown
- 2012-07-09 CN CN201280034688.4A patent/CN103717263B/en active Active
- 2012-07-09 EA EA201490053A patent/EA036047B1/en not_active IP Right Cessation
- 2012-07-09 AU AU2012282116A patent/AU2012282116B2/en active Active
- 2012-07-09 MX MX2014000479A patent/MX353931B/en active IP Right Grant
- 2012-07-10 US US13/545,708 patent/US8748585B2/en active Active
- 2012-09-07 UA UAA201400362A patent/UA116873C2/en unknown
-
2013
- 2013-12-26 CL CL2013003728A patent/CL2013003728A1/en unknown
-
2014
- 2014-01-13 ZA ZA2014/00254A patent/ZA201400254B/en unknown
- 2014-02-07 CO CO14026118A patent/CO7020848A2/en unknown
- 2014-03-21 US US14/222,421 patent/US20140294824A1/en not_active Abandoned
-
2016
- 2016-06-23 AU AU2016204274A patent/AU2016204274B2/en active Active
- 2016-11-10 US US15/348,774 patent/US20170260280A1/en not_active Abandoned
-
2017
- 2017-12-12 JP JP2017237351A patent/JP2018093869A/en active Pending
-
2018
- 2018-05-30 HR HRP20180858TT patent/HRP20180858T1/en unknown
- 2018-06-12 IL IL259979A patent/IL259979A/en unknown
- 2018-07-11 CY CY20181100726T patent/CY1120414T1/en unknown
- 2018-10-12 HK HK18113086.8A patent/HK1253936A1/en unknown
-
2019
- 2019-03-11 US US16/298,289 patent/US11407839B2/en active Active
- 2019-06-04 JP JP2019104214A patent/JP2019213520A/en active Pending
-
2022
- 2022-06-30 US US17/854,904 patent/US20220411526A1/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10196450B2 (en) | 2010-08-23 | 2019-02-05 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
US10851173B2 (en) | 2010-08-23 | 2020-12-01 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003728A1 (en) | Antagonist antibody or fragment thereof that binds to human ox40; epitope of the human ox40 extracellular domain that is bound by the aforementioned antibody; nucleic acid encoding the antibody; vector and host cell comprising said nucleic acid; method to produce the antibody; composition comprising the antibody; immunoconjugate; use to treat disorders mediated by ox40. | |
CO2018000887A2 (en) | Bispecific antibody constructs that bind to egfrviii and cd3 | |
HK1259303A1 (en) | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea | |
CL2021000717A1 (en) | Antibody constructs for cd70 and cd3. application divisional 270-2018 | |
BR112018015670A2 (en) | Bispecific t-cell antibody constructs | |
CO2018000211A2 (en) | Antibody molecules that bind to CD45 | |
CL2017002641A1 (en) | Bispecific antibody constructs against cdh3 and cd3 | |
CR20140146A (en) | ANTI-BODIES ANTI-CD134 (OX40) AND USES OF THE SAME | |
CL2013000930A1 (en) | Antibody for interleukin 17 (il-17); use of said antibody to treat psoriasis using il-17 antagonists. | |
CL2012002433A1 (en) | Isolated antibody or immunoreactive fragment thereof comprising a variable domain that specifically binds to an extracellular domain of the b7-h3 receptor; nucleic acid encoding it; hybridoma that secretes it; double affinity redirection reagent (dart) comprising it; pharmaceutical composition comprising it; and its use to treat cancer. | |
EA201492101A1 (en) | ANTIBODIES AGAINST FCRN | |
CL2015000696A1 (en) | Rheumatoid arthritis treatment | |
CL2016002509A1 (en) | Compositions to modulate the expression of sod-1 | |
CL2015000094A1 (en) | Compounds derived from imidazotriazincarbonitriles, protein kinase inhibitors; pharmaceutical composition that includes them; and its use to treat cancer, psoriasis and rheumatoid arthritis. | |
CL2014002750A1 (en) | Isolated antibody or fragment that binds to an inactive state of a her receptor; pharmaceutical composition comprising it; use of the antibody to treat cancer | |
EA201691974A1 (en) | ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | |
CL2013002811A1 (en) | Isolated monoclonal antibody that binds to an epitope of the human tissue factor pathway inhibitor; nucleic acid molecule that encodes it; pharmaceutical composition that includes it; and its use to treat deficiencies or genetic or acquired defects in coagulation. | |
CL2012002737A1 (en) | Humanized anti-cd40 antibody; polynucleotide encoding it; pharmaceutical composition comprising said antibody; and its use to block an immune response mediated by human cd40. | |
CL2011002482A1 (en) | Bispecific antibody that specifically binds to human erbb-3 and human c-met proteins; nucleic acid encoding it; pharmaceutical composition that includes it; and its use to treat cancer | |
BR112014004168A2 (en) | bispecific antibody, pharmaceutical composition, use of bispecific antibody, prokaryotic or eukaryotic host cell, antibody production method and invention | |
CL2011001994A1 (en) | Antagonist antibody that binds to human ox40 protein; DNA sequence encoding it; cloning or expression vector comprising said coding DNA; host cell comprising said cloning or expression vector; production process of said antibody; pharmaceutical composition comprising said antibody; medical use of said antibody; fusion protein comprising said antibody. | |
UY34387A (en) | COMPOSITIONS FOR THE TREATMENT OF Rheumatoid ARTHRITIS AND METHODS FOR USE. | |
EA201491602A1 (en) | STABILIZING AGENTS AND METHODS FOR THEIR USE | |
CL2015003049A1 (en) | Variants of pertuzumab and its evaluation | |
CL2014003339A1 (en) | Humanized anti-trka antibody with improved inhibitory properties; composition that includes it; and use to treat pain. |